Literature DB >> 22236192

Secreted clusterin in colon tumor cell models and its potential as diagnostic marker for colorectal cancer.

A M Rodríguez-Piñeiro1, A García-Lorenzo, S Blanco-Prieto, P Alvarez-Chaver, F J Rodríguez-Berrocal, M Páez de la Cadena, V S Martínez-Zorzano.   

Abstract

We studied the specific changes of the secreted protein clusterin and its cytoplasmic precursor regarding colorectal tumorigenesis, using in vitro differentiation of Caco-2 cells. In tumor-like stage, we observed an overexpression of both precursor and secreted clusterin, corroborated in the cell line SW-480. Noticeably, SW-620 cells (from a tumoral node, thus with metastatic capacity) did not show overexpression of either precursor or secreted clusterin, suggesting a downregulation related to local metastasis. We further investigated clusterin in serum, finding a significant increase in colorectal cancer patients, with 81% sensitivity, 79% specificity, and an area under the ROC curve of 0.85.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22236192     DOI: 10.3109/07357907.2011.630051

Source DB:  PubMed          Journal:  Cancer Invest        ISSN: 0735-7907            Impact factor:   2.176


  12 in total

Review 1.  Identifying human and murine M cells in vitro.

Authors:  Ana Klisuric; Benjamin Thierry; Ludivine Delon; Clive A Prestidge; Rachel J Gibson
Journal:  Exp Biol Med (Maywood)       Date:  2019-03-24

2.  Protein levels of clusterin and glutathione synthetase in platelets allow for early detection of colorectal cancer.

Authors:  Sarah Strohkamp; Timo Gemoll; Sina Humborg; Sonja Hartwig; Stefan Lehr; Sandra Freitag-Wolf; Susanne Becker; Bo Franzén; Ralph Pries; Barbara Wollenberg; Uwe J Roblick; Hans-Peter Bruch; Tobias Keck; Gert Auer; Jens K Habermann
Journal:  Cell Mol Life Sci       Date:  2017-08-28       Impact factor: 9.261

3.  N-glycoprotein SRMAtlas: a resource of mass spectrometric assays for N-glycosites enabling consistent and multiplexed protein quantification for clinical applications.

Authors:  Ruth Hüttenhain; Silvia Surinova; Reto Ossola; Zhi Sun; David Campbell; Ferdinando Cerciello; Ralph Schiess; Damaris Bausch-Fluck; George Rosenberger; Jingchung Chen; Oliver Rinner; Ulrike Kusebauch; Marián Hajdúch; Robert L Moritz; Bernd Wollscheid; Ruedi Aebersold
Journal:  Mol Cell Proteomics       Date:  2013-02-13       Impact factor: 5.911

4.  Serum clusterin as a tumor marker and prognostic factor for patients with esophageal cancer.

Authors:  Wei Guo; Xiao Ma; Christine Xue; Jianfeng Luo; Xiaoli Zhu; Jiaqing Xiang; Bo Lu; Hecheng Li
Journal:  Dis Markers       Date:  2014-12-10       Impact factor: 3.434

5.  Plasma clusterin as a candidate pre-diagnosis marker of colorectal cancer risk in the Florence cohort of the European Prospective Investigation into Cancer and Nutrition: a pilot study.

Authors:  Michela Bertuzzi; Cristina Marelli; Renzo Bagnati; Alessandro Colombi; Roberto Fanelli; Calogero Saieva; Marco Ceroti; Benedetta Bendinelli; Saverio Caini; Luisa Airoldi; Domenico Palli
Journal:  BMC Cancer       Date:  2015-02-14       Impact factor: 4.430

6.  Clusterin, a gene enriched in intestinal stem cells, is required for L1-mediated colon cancer metastasis.

Authors:  Beny Shapiro; Piera Tocci; Gal Haase; Nancy Gavert; Avri Ben-Ze'ev
Journal:  Oncotarget       Date:  2015-10-27

Review 7.  Cell Line Secretome and Tumor Tissue Proteome Markers for Early Detection of Colorectal Cancer: A Systematic Review.

Authors:  Megha Bhardwaj; Vanessa Erben; Petra Schrotz-King; Hermann Brenner
Journal:  Cancers (Basel)       Date:  2017-11-16       Impact factor: 6.639

8.  Antisense oligonucleotide against clusterin regulates human hepatocellular carcinoma invasion through transcriptional regulation of matrix metalloproteinase-2 and E-cadherin.

Authors:  Dong Chen; Yan Wang; Kejun Zhang; Xuelong Jiao; Bomin Yan; Jun Liang
Journal:  Int J Mol Sci       Date:  2012-08-23       Impact factor: 6.208

9.  Aberrant gene expression in mucosa adjacent to tumor reveals a molecular crosstalk in colon cancer.

Authors:  Rebeca Sanz-Pamplona; Antoni Berenguer; David Cordero; David G Molleví; Marta Crous-Bou; Xavier Sole; Laia Paré-Brunet; Elisabet Guino; Ramón Salazar; Cristina Santos; Javier de Oca; Xavier Sanjuan; Francisco Rodriguez-Moranta; Victor Moreno
Journal:  Mol Cancer       Date:  2014-03-05       Impact factor: 27.401

10.  Secretory Clusterin Mediates Oxaliplatin Resistance via the Gadd45a/PI3K/Akt Signaling Pathway in Hepatocellular Carcinoma.

Authors:  Xin Wang; Fang Zou; Jingtao Zhong; Longtao Yue; Fuhai Wang; Honglong Wei; Guangsheng Yang; Tao Jin; Xiaofeng Dong; Jie Li; Peng Xiu
Journal:  J Cancer       Date:  2018-04-06       Impact factor: 4.207

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.